Signant Health Acquires Ametris to Create Integrated eCOA and Digital Biomarker Platform
核心洞察
Signant Health (搜索) has completed its acquisition of Ametris (搜索) (formerly ActiGraph (搜索)), a global digital health solutions provider specializing in wearable-derived digital outcome measures.
The strategic acquisition creates an end-to-end platform that integrates patient-reported outcomes through eCOA with continuous sensor data from wearables.
The combined platform addresses the growing need for multiple lines of evidence in clinical trials, particularly in CNS (搜索) and complex therapeutic areas where sponsors require comprehensive efficacy cases.
Signant Health (搜索) has completed its acquisition of Ametris (搜索) (formerly ActiGraph (搜索)), a global digital health solutions provider, creating an integrated platform that combines electronic clinical outcome assessments (eCOA) with wearable-derived digital outcome measures. The strategic acquisition addresses the increasing demand for comprehensive evidence generation in clinical trials.
Addressing Multimodal Evidence Requirements
Clinical trials increasingly require multiple lines of evidence to demonstrate meaningful treatment benefit. Previously, sponsors needed to manage multiple vendors, reconcile disparate datasets, and navigate complex integration challenges when combining patient-reported outcomes with objective sensor data. The acquisition eliminates these operational complexities by providing a unified platform.
"This acquisition represents our commitment to advancing what's possible in clinical evidence generation – building an end-to-end platform that integrates what patients say and what their bodies show," said Roger Smith, chief executive officer of Signant. "Patient-reported outcomes through eCOA capture what matters most – how patients feel and function in their daily lives."
Platform Integration and Capabilities
The combined platform integrates Signant's industry-leading eCOA solutions with Ametris (搜索)' validated, wearable-derived digital outcome measures. This creates a purpose-built system that captures both the patient voice and objective, clinically meaningful outcome measures within a single workflow.
"Ametris (搜索) has spent two decades developing regulatory-aligned wearable-derived measures of physical activity and function, captured objectively in patients' natural environments," said Jeremy Wyatt, chief executive officer of Ametris. "Joining Signant allows us to accelerate our vision of truly integrated multimodal evidence generation."
Therapeutic Focus and Applications
The integrated platform provides particular value in CNS (搜索) and other complex therapeutic areas where sponsors need multiple lines of evidence to demonstrate meaningful benefit. By combining subjective patient experiences with objective sensor measurements, the platform enables sponsors to build stronger, more comprehensive efficacy cases.
The acquisition brings together Signant's leadership in clinical outcome assessments with Ametris (搜索)' expertise in sensor-based measurement, creating what the companies describe as a unique offering in the industry.
Development Roadmap
The combined company will maintain Ametris (搜索)' innovation roadmap while investing significantly in platform integration capabilities. Near-term priorities include unified data flows and workflows, coordinated deployment tools, and integrated analytics.
Future development plans include AI and machine learning algorithms that identify patterns across both modalities, enabling novel digital and composite outcome measures, and real-time insights that could transform trial monitoring.
Company Background
Founded in 2004, Ametris (搜索) has established itself as a provider of end-to-end digital health solutions, combining advanced wearables, regulatory-aligned analytics, and scientific support for clinical trials. The company's platform covers every phase from study design to regulatory submission.
Signant Health (搜索) has operated for more than 25 years, serving over 600 sponsors and CROs of all sizes, including all Top 20 pharmaceutical companies. The company provides solutions for remote and site-based eCOA, EDC, eConsent, RTSM, supply chain management, and data quality analytics across traditional, virtual, and hybrid trial models.